NeoImmuneTech Enters into Exclusive License Agreement with Ubix Therapeutics to Develop Drug Candidates Including T Cell Suppressor Blockade
- Category: More News
- Published on Monday, 23 March 2020 16:11
- Hits: 1067
New NeoImmuneTech research institute to lead preclinical development
ROCKVILLE, MA, USA I March 23, 2020 INeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company today announced it has entered into an exclusive license agreement with Ubix Therapeutics, Inc. (UBIX) to develop up to three drug candidates utilizing UBIX’s Degraducer® platform technology which enables target protein degradation. Under the terms of the agreement, NeoImmuneTech, Inc. (NIT) acquired the exclusive worldwide rights to research, develop, and commercialize drug candidates, in exchange for development and sales milestones, as well as royalties. The preclinical development work will be conducted in NIT’s new, state-of-the-art research institute located in the Republic of Korea.
“We are excited to broaden our T cell-focused portfolio to include novel T cell suppressor blockades, in addition to our clinically advanced T cell amplifier, NT-I7,” said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NIT. “We have great confidence in UBIX’s Degraducer® technology and believe this collaboration will open up new opportunities for NIT to develop multiple potent novel therapeutics for the treatment of cancers and infectious diseases with these three additional novel targets.”
“We are very pleased to start this business collaboration with NIT, which has a promising clinical-stage T cell immunotherapy asset as well as an excellent management team with extensive experience in oncology drug development,” said BK Seo, President and Chief Executive Officer of UBIX. “By working collaboratively with the NIT team, we are confident that the candidates we discover will be properly assessed for their potential as novel cancer immunotherapies.”
NT-I7 (also known as Hyleukin-7™) is the only clinical-stage long-acting human IL-7 and is uniquely positioned to address unmet medical needs in immuno-oncology. IL-7 is a fundamental cytokine for naïve and memory T-cell development and for sustaining immune response to chronic antigens (as in cancer). NT-I7 exhibits a favorable PK/PD and safety profile, making it an ideal combination partner for immunotherapy standard of care (SOC) such as Checkpoint Inhibitor and CAR-T therapies. NT-I7 is being studied in multiple clinical trials in solid tumors, and being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology. NIT is led by the scientific founder and inventor of NT-I7 and complemented by a strong executive team with rich industry experience at companies such as Novartis, BMS, GSK, Pfizer, Amgen, Eli Lilly, MedImmune/AstraZeneca and PwC. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
About Ubix Therapeutics
Ubix Therapeutics, Inc. (UBIX) develops novel drugs based on Degraducer® platform technology. Degraducer® is a powerful next generation inhibitor technology that enables targeting of disease-related targets that were previously undruggable. UBIX is focusing on cancer immunotherapy using its own technology based on thorough understanding of the human immune system and target proteins. For more information, please visit http://en.ubixtrx.com.
SOURCE: Ubix Therapeutics